Sidra N Bonner1, Cheryl Clark2, Nancy L Keating3, Elena M Kouri4, Rachel A Freedman5. 1. University of California-San Francisco School of Medicine, San Francisco, CA. 2. Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA. 3. Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA; Department of Health Care Policy, Harvard Medical School, Boston, MA. 4. Department of Health Care Policy, Harvard Medical School, Boston, MA. 5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address: Rachel_Freedman@dfci.harvard.edu.
Abstract
BACKGROUND: The effect of racial residential segregation on breast cancer treatment disparities is unclear. We examined whether racial segregation is associated with adjuvant treatment receipt and patient knowledge of disease. PATIENTS AND METHODS: We surveyed a population-based sample of women in Northern California with stage I to III breast cancer diagnosed in 2010 to 2011 (participation rate = 68.5%, 500 patients). For black, Hispanic, and white women, we measured black and Hispanic segregation using the location quotient (LQ) of racial residential segregation, a proportional measure of the size of a minority group in the census tract compared with the larger metropolitan statistical area. We categorized LQ values for black and Hispanic participants into quartiles, with quartile 1 representing a lower relative level of segregation than quartile 4. We used multivariable logistical regression to assess the odds of receiving guideline-recommended adjuvant therapy and patient knowledge of tumor characteristics according to relative residential segregation. RESULTS: We observed greater residential segregation for black versus Hispanic patients (P < .05). Overall, there were no treatment differences according to Hispanic or black LQ, except for black LQ quartile 3 (vs. 1) for which we observed higher odds of hormonal therapy. Knowledge of disease did not vary according to black LQ, but patients in the Hispanic LQ quartile 3 (vs. quartile 1) had less tumor knowledge. CONCLUSION: We did not find clear associations for racial residential segregation and treatment or cancer knowledge in Northern California, an area with low levels of segregation. Additional research should assess the effect of segregation on breast cancer treatment disparities in a variety of geographical locations.
BACKGROUND: The effect of racial residential segregation on breast cancer treatment disparities is unclear. We examined whether racial segregation is associated with adjuvant treatment receipt and patientknowledge of disease. PATIENTS AND METHODS: We surveyed a population-based sample of women in Northern California with stage I to III breast cancer diagnosed in 2010 to 2011 (participation rate = 68.5%, 500 patients). For black, Hispanic, and white women, we measured black and Hispanic segregation using the location quotient (LQ) of racial residential segregation, a proportional measure of the size of a minority group in the census tract compared with the larger metropolitan statistical area. We categorized LQ values for black and Hispanic participants into quartiles, with quartile 1 representing a lower relative level of segregation than quartile 4. We used multivariable logistical regression to assess the odds of receiving guideline-recommended adjuvant therapy and patient knowledge of tumor characteristics according to relative residential segregation. RESULTS: We observed greater residential segregation for black versus Hispanic patients (P < .05). Overall, there were no treatment differences according to Hispanic or black LQ, except for black LQ quartile 3 (vs. 1) for which we observed higher odds of hormonal therapy. Knowledge of disease did not vary according to black LQ, but patients in the Hispanic LQ quartile 3 (vs. quartile 1) had less tumor knowledge. CONCLUSION: We did not find clear associations for racial residential segregation and treatment or cancer knowledge in Northern California, an area with low levels of segregation. Additional research should assess the effect of segregation on breast cancer treatment disparities in a variety of geographical locations.
Authors: John Z Ayanian; Elizabeth A Chrischilles; Robert H Fletcher; Mona N Fouad; David P Harrington; Katherine L Kahn; Catarina I Kiefe; Joseph Lipscomb; Jennifer L Malin; Arnold L Potosky; Dawn T Provenzale; Robert S Sandler; Michelle van Ryn; Robert B Wallace; Jane C Weeks; Dee W West Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Carol Smigal; Ahmedin Jemal; Elizabeth Ward; Vilma Cokkinides; Robert Smith; Holly L Howe; Michael Thun Journal: CA Cancer J Clin Date: 2006 May-Jun Impact factor: 508.702
Authors: Kiarri N Kershaw; Whitney R Robinson; Penny Gordon-Larsen; Margaret T Hicken; David C Goff; Mercedes R Carnethon; Catarina I Kiefe; Stephen Sidney; Ana V Diez Roux Journal: JAMA Intern Med Date: 2017-07-01 Impact factor: 21.873
Authors: Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-10-29 Impact factor: 508.702
Authors: Lisa D Chew; Joan M Griffin; Melissa R Partin; Siamak Noorbaloochi; Joseph P Grill; Annamay Snyder; Katharine A Bradley; Sean M Nugent; Alisha D Baines; Michelle Vanryn Journal: J Gen Intern Med Date: 2008-03-12 Impact factor: 5.128
Authors: V Saravanabavan; V Emayavaramban; V Thangamani; I K Manonmani; R S Suja Rose; D Balaji; R Rahamath Nisha; K Kannadasan; S Vinothkanna; C Vinothini Journal: GeoJournal Date: 2022-06-28